Confocal Laser Endomicroscopy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy defines Blue Cross Blue Shield of North Carolina's coverage position on confocal laser endomicroscopy (CLE) for diagnostic and adjunctive use during endoscopy, and is directed to providers requesting coverage for members. It covers all reported clinical applications and device types described in the document.
No material clinical or coverage changes in this revision.
Coverage Determination
Not covered — investigational
Coverage determination
BCBSNC does not provide coverage for investigational services or procedures. Claims for CLE will be denied as investigational.
Coverage criteria (not present in provided chunks)
Covered when ALL of the following are met:
Policy Guidelines summarize diagnostic accuracy studies and randomized trials for colorectal lesions, Barrett's esophagus surveillance, post‑treatment assessment, and non‑GI lesions but conclude evidence is insufficient to demonstrate improved net health outcome.
When it is covered: Not applicable. The policy statement for confocal laser endomicroscopy (CLE) stipulates that use of CLE is considered investigational for all applications, and therefore BCBSNC does not provide coverage for CLE under this policy.
Claims for CLE are subject to medical necessity review and may be denied because the technology is classified as investigational for all indications in this policy. Providers should refer to the member's benefit contract and subscriber certificate for coverage determinations beyond this policy statement.
There are no specific indications listed as covered for confocal laser endomicroscopy in this policy. The "When it is covered" field is documented as Not applicable, and the policy explicitly states that use of CLE is considered investigational and therefore not covered.
No explicit exclusion conditions beyond the investigational classification are listed in the available policy text. Coverage decisions, exclusions based on contract terms, or other administrative limits should be determined by the member's benefit plan and subscriber certificate; this policy does not enumerate additional exclusion scenarios.
The evidence summarized in the policy guidelines indicates that, although diagnostic accuracy studies and several randomized trials and meta-analyses have evaluated CLE as an adjunct to colonoscopy, for Barrett’s esophagus surveillance, and for assessment after endoscopic treatment, the available data are insufficient to demonstrate an improvement in net health outcome. Reported pooled sensitivity and specificity estimates vary (pooled sensitivity commonly reported in the range of 81%–94% and pooled specificity of 88%–95% in systematic reviews), but uncertainty remains whether CLE can reliably replace standard histopathologic evaluation or established surveillance protocols.
For these reasons the policy concludes that the evidence is insufficient to determine that CLE used as an adjunct to standard procedures results in improved health outcomes; consequently, CLE is not considered medically necessary for targeting biopsies in Barrett’s esophagus, as an adjunct to colonoscopy, for post-endoscopic treatment assessment, or for other non-gastrointestinal lesion diagnoses described in the literature.
Historical policy notes: a new BCBSNC policy issued on 2/26/13 recorded that use of confocal laser endomicroscopy is considered investigational. The policy became effective 5/28/13 and has undergone periodic updates (references, minor revisions, and advisory reviews) with no change to the core policy statement that CLE is investigational.
Subsequent implementation and update entries (2013–2023) document periodic review by Specialty Matched Consultant Advisory Panels and Medical Director reviews, additions to the Billing/Coding section (for example, adding code 0397T effective 1/1/16), and reference updates, while preserving the investigational coverage stance.
Applicable Codes and Billing
| 43206 | Esophagoscopy, flexible, transoral; with optical endomicroscopy, with or without imaging of the mucosa |
| 43252 | Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy, including diagnostic evaluation |
| 88375 | Morphometric analysis, tumor, per specimen (listed as applicable code in policy) |
| 0397T | Optical endomicroscopy, diagnostic, any type (listed as applicable code in policy) |
| 0397T | Added to Billing/Coding section effective 1/1/16 (code listed in update history) |
Provider Responsibilities and Authorization
Prior authorization not specified — refer to benefit contract
The document does not specify prior authorization procedures or list particular authorization requirements; providers must refer to the member's benefit booklet or group contract for prior authorization rules and procedures.
- Member benefits and prior authorization requirements vary by benefit design; review the Member's Benefit Booklet.
- Benefits and eligibility are determined by the group contract and subscriber certificate.
Step therapy — none specified
No step therapy requirements for confocal laser endomicroscopy are described in this policy segment.
- Policy text does not list any step therapy or prerequisite treatment sequences.
Step therapy — confirmation none described
This policy segment contains no additional statements imposing step therapy; the policy consistently does not describe step therapy requirements.
- No step therapy described in implementation/update notes or billing/coding section.
Records required for medical necessity review — submit full medical records
BCBSNC may request medical records to determine medical necessity; when records are requested, letters of support alone are insufficient unless they include all specific information needed for the determination.
- Medical records may be requested to determine medical necessity.
- Letters of support/explanation are often useful but not sufficient unless all required information is included.
Documentation and administrative notes — policy informational; verify benefits/eligibility
Policy implementation and update notes clarify that medical policy is informational only; benefits and eligibility are determined by the group contract and subscriber certificate, and the policy should not be treated as an authorization or guarantee of payment.
- Medical policy is not an authorization, certification, explanation of benefits or a contract.
- Benefits and eligibility must be determined from the group contract and subscriber certificate in effect at the time services are rendered.
Investigational — claims may be denied
Claims for confocal laser endomicroscopy will be denied because the policy states use of CLE is considered investigational for all applications.
- Use of confocal laser endomicroscopy is considered investigational for all applications.
- BCBSNC does not provide coverage for investigational services or procedures.
Codes subject to review — reimbursement not guaranteed
Inclusion of codes in the billing/coding section does not guarantee reimbursement; claims billed with the listed codes may be reviewed and denied if the service is judged investigational.
Provider actions — authorization/denial triggers not specified
This document segment does not specify provider actions that would trigger explicit authorizations or denials; no additional authorization triggers are listed in these chunks.
- Policy text in the cited implementation/update notes does not list explicit authorization or denial triggers.
Clinical Background
Confocal laser endomicroscopy (CLE) is an endoscopic imaging technique that uses a low‑power laser and confocal optics to obtain in vivo, high‑magnification microscopic images of the mucosal epithelium during endoscopy. Two system types are described: endoscope‑based CLE, which integrates confocal optics at the endoscope tip, and probe‑based CLE, which uses a fiber‑optic probe passed through the endoscope channel. CLE requires contrast agents (commonly intravenous fluorescein), has a limited field and depth of view compared with standard endoscopic imaging, and relies on lesion classification systems and operator interpretation, which contribute to a learning curve for clinical use.
Definitions and Device Types
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.